USANA Health Sciences (USNA) Projected to Post Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is expected to issue its quarterly earnings data after the market closes on Tuesday, April 22nd. Analysts expect the company to announce earnings of $0.74 per share and revenue of $243.08 million for the quarter. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS.Persons that wish to listen to the company’s earnings conference call can do so using this link.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The firm had revenue of $213.61 million during the quarter, compared to analyst estimates of $208.82 million. On average, analysts expect USANA Health Sciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Stock Down 0.6 %

NYSE USNA opened at $24.59 on Tuesday. The firm has a market cap of $464.87 million, a P/E ratio of 8.69, a price-to-earnings-growth ratio of 0.93 and a beta of 1.00. The company’s 50 day moving average is $29.02 and its 200-day moving average is $33.90. USANA Health Sciences has a 12-month low of $23.67 and a 12-month high of $49.78.

Insider Activity

In other USANA Health Sciences news, insider Joshua Foukas sold 5,732 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Mulham Mulham sold 3,234 shares of USANA Health Sciences stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $32.98, for a total value of $106,657.32. Following the sale, the insider now owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. This trade represents a 20.20 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,920 shares of company stock worth $500,285. 0.33% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. DA Davidson lowered their target price on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. Finally, StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.